|
Targeting EGFR in Triple-Negative Breast Cancer
Breast tumors which are neither positive for ER, PR, or HER2 are colloquially referred to as triple-negative, due to their lack of either hormonal or growth factor related marker expression. These tumors are not responsive to either hormonal therapy or HER2-targeted agents, and thus chemotherapy is often the only effective treatment. Interestingly, expression of the HER2-related gene, HER1 — more commonly known as epidermal growth factor receptor (EGFR) — has been seen in expression profiles of triple-negative tumors, and thus EGFR-targeted therapy may be efficacious in this setting
To read full article:
http://www.curetoday.com/sabcs2007/sat/brief.php
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
|